Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.31 |
| ▸ | SYNJ2 | O15056 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18392791 | 1.00 | L3MBTL1 (0.39) | L3MBTL1MAPTALDH1A1HIF1ACD209 | |
| SCHEMBL20381805 | 1.00 | L3MBTL1 (0.39) | L3MBTL1MAPTALDH1A1HIF1ACD209 | |
| SCHEMBL25222379 | 1.00 | L3MBTL1 (0.39) | L3MBTL1MAPTALDH1A1HIF1ACD209 | |
| SCHEMBL25585820 | 1.00 | L3MBTL1 (0.39) | L3MBTL1MAPTALDH1A1HIF1ACD209 | |
| SCHEMBL19036942 | 0.90 | ALDH1A1 (0.33) | L3MBTL1MAPTALDH1A1HIF1A | |
| SCHEMBL16201890 | 0.90 | ALDH1A1 (0.33) | L3MBTL1MAPTALDH1A1HIF1A | |
| SCHEMBL16201903 | 0.90 | ALDH1A1 (0.33) | L3MBTL1MAPTALDH1A1HIF1A | |
| SCHEMBL20381837 | 0.84 | LGALS8 (0.34) | L3MBTL1CD209LGALS8 | |
| SCHEMBL18393028 | 0.84 | LGALS8 (0.34) | L3MBTL1CD209LGALS8 | |
| SCHEMBL13482776 | 0.83 | LGALS8 (0.43) | L3MBTL1MAPTALDH1A1HIF1ACD209 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023603-B2 | Preparation of monosaccharides, disaccharides, trisaccharides, and pentasaccharides of heparinoids | FORMOSA LABORATORIES, INC. (TW) | 2018-07-17 | — | — | US | disclosed |
| US-20170015695-A1 | PREPARATION OF MONOSACCHARIDES, DISACCHARIDES, TRISACCHARIDES, AND PENTASACCHARIDES OF HEPARINOIDS | FORMOSA LABORATORIES, INC. (TW) | 2017-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023603-B2 | Preparation of monosaccharides, disaccharides, trisaccharides, and pentasaccharides of heparinoids | HPSE, DDOST, FUT5 | L3MBTL1 4817/4885MAPT 4502/4885ALDH1A1 3929/4885 |
| US-20170015695-A1 | PREPARATION OF MONOSACCHARIDES, DISACCHARIDES, TRISACCHARIDES, AND PENTASACCHARIDES OF HEPARINOIDS | HPSE, DDOST, FUT5 | L3MBTL1 4817/4885MAPT 4502/4885ALDH1A1 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.